Does the FMO3 rs2266780 AA genotype support efficient conversion of TMA to TMAO?

Flavin-containing monooxygenase 3 (FMO3) is the primary hepatic enzyme responsible for oxidizing gut-derived trimethylamine (TMA) into trimethylamine N-oxide (TMAO), a compound closely monitored in cardiovascular and metabolic health.

Mechanistic pathways

• Wild-type reference state: The rs2266780 AA genotype represents the E308/E308 (glutamate) wild-type reference form of the FMO3 gene. This genotype maintains standard hepatic FMO3 protein abundance and baseline catalytic architecture.
• Avoidance of enzymatic impairment: Unlike variant alleles (such as the G or Gly308 variant) that are linked to decreased hepatic FMO3 protein levels and diminished in vivo TMAO synthesis, the AA genotype preserves normal protein expression. It does not exhibit the catalytic deficits associated with severe FMO3 loss-of-function mutations that lead to trimethylaminuria (TMAU).

Metabolic and clinical implications

• Efficient TMA conversion: By maintaining standard catalytic efficiency, the rs2266780 AA genotype supports the efficient clearance of TMA and its conversion into TMAO.
• Role of compounding variables: Although the AA genotype represents the baseline genetic architecture required for normal FMO3 function, systemic TMAO levels are highly dynamic. Ultimate circulating concentrations are also dictated by environmental factors, including the intake of dietary precursors (like choline and L-carnitine), gut microbiome composition, and renal clearance capacity.

Bottom line

• The FMO3 rs2266780 AA genotype represents the fully functional wild-type reference state of the enzyme, supporting efficient and normal hepatic oxidation of TMA to TMAO.